Press Releases

Biocon Biologics  /  Press Releases

Biocon Q4FY24 Revenue at Rs 3,966 Cr, EBITDA at Rs 964 Cr; Net Profit (before exceptional items) at Rs 144 Cr

  • Posted by: Biocon Biologics

Biocon Biologics Enters a Long-term Commercial Collaboration with Eris Lifesciences to Expand Patient Access in India

  • Posted by: Biocon Biologics

Biocon Biologics Secures US Market Entry Date for Bmab 1200, a Proposed Biosimilar to Stelara®

  • Posted by: Biocon Biologics

Biocon Included in S&P Global Sustainability Yearbook 2024

  • Posted by: Biocon Biologics

Biocon Biologics Partners with Sandoz Australia for Biosimilars Trastuzumab and Bevacizumab

  • Posted by: Biocon Biologics

Biocon Q3FY24 Revenue at Rs 4,519 Cr, Up 50%; Biosimilars Up 65%; Research Services Up 9%; EBITDA at Rs 1,492 Cr, Up 106%; Net Profit at Rs 660 Cr Pre-Paid USD 200 Mn towards Debt Reduction

  • Posted by: Biocon Biologics

Oral Cancer Task Force’s Consensus Guidelines for Head & Neck Cancer Recognized Among 13 Worldwide Clinical Practice Guidelines

  • Posted by: Biocon Biologics

Biocon Biologics Partners with Sandoz for the Distribution of “Adalimumab BS Subcutaneous Injection [FKB]” in Japan

  • Posted by: Biocon Biologics

Biocon Biologics Concludes Integration of Acquired Biosimilars Business in ~120 countries

  • Posted by: Biocon Biologics

Biocon Biologics Recognized as an Asia IP Elite for 2023, IPR Team adjudged as the Team of the Year

  • Posted by: Biocon Biologics
Share